HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy

Fu, Shan; Zhang, Qiqi; Jing, Ruirui; Zu, Cheng; Ni, Fang; Lv, Yuqi; Cui, Jiazhen; Zheng, Haiqiong; Zhang, Yanlei; Zhang, Mingming; Wei, Guoqing; Cen, Zenan; Chang, Alex H.; Hu, Yongxian; Huang, He

doi:10.1038/s41409-023-01960-2

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, it is crucial to consider the potential renal and bone health consequences that may arise from using tenofovir. In a study, Fu et al [ 127 ] proposed that tenofovir possesses strong anti-viral properties and beneficial resistance characteristics, making it an essential component in treating HBV reactivation. This highlights the significance of tailoring treatment approaches to individual patients to maximize outcomes’ effectiveness.…”

Section: Management Strategies For Hbv Reactivationmentioning

confidence: 99%

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies

Ma,

Yan,

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) reactivation is a clinically significant challenge in disease management. This review explores the immunological mechanisms underlying HBV reactivation, emphasizing disease progression and management. It delves into host immune responses and reactivation’s delicate balance, spanning innate and adaptive immunity. Viral factors’ disruption of this balance, as are interactions between viral antigens, immune cells, cytokine networks, and immune checkpoint pathways, are examined. Notably, the roles of T cells, natural killer cells, and antigen-presenting cells are discussed, highlighting their influence on disease progression. HBV reactivation’s impact on disease severity, hepatic flares, liver fibrosis progression, and hepatocellular carcinoma is detailed. Management strategies, including anti-viral and immunomodulatory approaches, are critically analyzed. The role of prophylactic anti-viral therapy during immunosuppressive treatments is explored alongside novel immunotherapeutic interventions to restore immune control and prevent reactivation. In conclusion, this comprehensive review furnishes a holistic view of the immunological mechanisms that propel HBV reactivation. With a dedicated focus on understanding its implications for disease progression and the prospects of efficient management strategies, this article contributes significantly to the knowledge base. The more profound insights into the intricate interactions between viral elements and the immune system will inform evidence-based approaches, ultimately enhancing disease management and elevating patient outcomes. The dynamic landscape of management strategies is critically scrutinized, spanning anti-viral and immunomodulatory approaches. The role of prophylactic anti-viral therapy in preventing reactivation during immunosuppressive treatments and the potential of innovative immunotherapeutic interventions to restore immune control and proactively deter reactivation.

show abstract

Section: Management Strategies For Hbv Reactivationmentioning

confidence: 99%

Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies

Ma,

Yan,

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

Hepatitis B virus reactivation associated with CAR T-cell therapy

Lin,

Dai,

Huang

et al. 2024

Holist Integ Oncol

View full text Add to dashboard Cite

Patients with hematological malignancies who also have a hepatitis B virus (HBV) infection need to be aware of the potential risk of HBV reactivation when undergoing anti-cancer treatments. Among these treatments, CAR T-cell therapy has gained significant attention as a promising option, but it also raises concerns regarding HBV reactivation. This review aims to provide an overview of published reports on HBV reactivation during CAR T-cell therapy, along with an assessment of the effectiveness of prophylactic antiviral therapy. Additionally, we propose a systematic approach for monitoring and managing HBV reactivation during CAR T-cell therapy to enhance the safety of this treatment for patients with HBV infection.

show abstract